FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model

Korean Journal of Radiology

Volumn 8, Issue 3, 2007, Pages 216-224

  Hee, Sun Park ^a   Jin, Wook Chung ^a,b   Hwan, Jun Jae ^a   Young, Il Kim ^a   Kyu, Ri Son ^a   Min, Jong Lee ^a   Jae, Hyung Park ^a   Won, Jun Kang ^b   Jung, Hwan Yoon ^b   Chung, Hesson ^c   Lee, Kichang ^d  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

^d Chonbuk National University   (South Korea)

Author keywords

Liver neoplasm, therapeutic radiology; Liver, interventional procedure; Liver, PET

Indexed keywords

BROMOPYRUVIC ACID; ENZYME INHIBITOR; FLUORODEOXYGLUCOSE F 18; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVIC ACID DERIVATIVE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; DISEASE MODEL; DRUG ANTAGONISM; FEASIBILITY STUDY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; NECROSIS; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RABBIT; SCINTISCANNING;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEASIBILITY STUDIES; FLUORODEOXYGLUCOSE F18; INFUSIONS, INTRA-ARTERIAL; INJECTIONS, INTRA-ARTERIAL; LIVER NEOPLASMS, EXPERIMENTAL; NECROSIS; POSITRON-EMISSION TOMOGRAPHY; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVATES; RABBITS; RADIOPHARMACEUTICALS;

EID: 34249987354     PISSN: 12296929     EISSN: None     Source Type: Journal    
DOI: 10.3348/kjr.2007.8.3.216     Document Type: Article

References (32)

1. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH conference. Hepatocellular carcinoma. Ann Intern Med 1988;108:390-401
2. Rustgi VK. Epidemiology of hepatocellular carcinoma. Gastroenterol Clin North Am 1987;16:545-551
3. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56:918-928
4. Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13:S211-S221
5. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983;148:397-401
6. Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997;25:259-262
7. Pedersen PL. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 1978;22:190-274
8. Arora KK, Pedersen PL. Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. J Biol Chem 1988;263:17422-17428
9. Greiner EF, Guppy M, Brand K. Glucose is essential for proliferation and the glycolytic enzyme induction that provokes a transition to glycolytic energy production. J Biol Chem 1994;269:31484-31490
10. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 2001;276:43407-43412
11. Weinhouse S. Glycolysis, respiration, and anomalous gene expression in experimental hepatomas: G.H.A. Clowes memorial lecture. Cancer Res 1972;32:2007-2016
12. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 2002;1555:14-20
13. Shinohara Y, Ichihara J, Terada H. Remarkably enhanced expression of the type II hexokinase in rat hepatoma cell line AH130. FEBS Lett 1991;291:55-57
14. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem 1995;270:16918-16925
15. Nakashima RA, Paggi MG, Scott LJ, Pedersen PL. Purification and characterization of a bindable form of mitochondrial bound hexokinase from the highly glycolytic AS-30D rat hepatoma cell line. Cancer Res 1988;48:913-919
16. Ko YH, Pedersen PL, Geschwind JF. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 2001;173:83-91
17. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res 2002;62:3909-3913
18. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978;19:1154-1161
19. Kapoor V, McCook BM, Torok FS. An introduction to PET-CT imaging. Radiographics 2004;24:523-543
20. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004;231:305-332
21. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004;324:269-275
22. Okada M, Kudo S, Miyazaki O, Saino T, Ekimoto H, Iguchi H, et al. Antitumoral efficacy and pharmacokinetic properties of pirarubicin upon hepatic intra-arterial injection in the rabbit V x 2 tumour model. Br J Cancer 1995;71:518-524
23. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 2005;42:358-364
24. Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980;21:670-675
25. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623-648
26. Oya N, Nagata Y, Ishigaki T, Abe M, Tamaki N, Magata Y, et al. Evaluation of experimental liver tumors using fluorine-18-2-fluoro-2-deoxy-D-glucose PET. J Nucl Med 1993;34:2124-2129
27. Messa C, Choi Y, Hoh CK, Jacobs EL, Glaspy JA, Rege S, et al. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr 1992;16:684-689
28. Nagata Y, Yamamoto K, Hiraoka M, Abe M, Takahashi M, Akuta K, et al. Monitoring liver tumor therapy with [18F]FDG positron emission tomography. J Comput Assist Tomogr 1990;14:370-374
29. Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 1992;33:333-339
30. Torizuka T, Tamaki N, Inokuma T, Magata Y, Yonekura Y, Tanaka A, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994;35:1965-1969
31. Oya N, Nagata Y, Tamaki N, Takagi T, Murata R, Magata Y, et al. FDG-PET evaluation of therapeutic effects on VX2 liver tumor. J Nucl Med 1996;37:296-302
32. Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, Verhoef G, et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging 2003;30:682-688